CD66a (human homolog of rat cell-cell adhesion molecule, also known as biliary glycoprotein) is a cell surface protein of the immunoglobulin family. CD66a has been shown to mediate homotypic cell adhesion. Aside from this, no other functions of this molecule have been demonstrated. We have observed previously that CD66a protein expression is lost in most prostate tumors, suggesting that the down-regulation of CD66a is associated with the abnormal growth of prostate cells. CD66a is homologous (65% identity) to rat cell-cell adhesion molecule, which has been shown to have tumor-suppressive activity. This homology suggests the possibility that CD66a might also be a tumor suppressor. In this report, we show that restoring CD66a expression in DU145 human prostate cancer cells by adenovirus (Ad)-mediated gene transfer dramatically altered the malignant phenotype of these cells, as evidenced by their reduced ability to form tumors in a xenograft animal model. This result suggests that loss of CD66a protein plays an important role in the development of prostate cancer, and that restoring CD66a expression might provide an effective treatment for prostate cancer. We further explored the possibility of using Ad vectors to deliver CD66a as a potential therapeutic agent for prostate cancer. Direct injection of Ad-CD66a, an Ad vector carrying the CD66a gene, into DU145 tumors in mice significantly suppressed the growth of these tumors. This antitumor activity of CD66a was found to be dose-dependent. These results suggest that CD66a has tumor-suppressive activity and that Ad-CD66a is a potential therapeutic agent for prostate cancer treatment.
P
rostate cancer is the most common malignancy and the second leading cause of cancer mortality in the adult male population. According to the American Cancer Society statistics from 1997, there are ϳ334,500 new cases of prostate cancer in the United States each year, and ϳ41,800 deaths annually can be directly attributed to this disease. Treatments for localized disease remain somewhat controversial, and effective treatment for androgen-independent prostate cancer has remained elusive. The current standard treatment for patients with advanced androgen-independent disease is largely palliative; few clinical advances have been made in halting the progression of this disease. Thus, new strategies for the treatment of locally advanced or androgen-independent prostate cancer are desperately needed to reduce mortality.
We observed previously that androgen could regulate the expression of the cell-cell adhesion molecule (C-CAM) in the rat prostate. 1 This observation suggests that C-CAM may participate in androgen-regulated prostate growth and differentiation. In a related study on the role of C-CAM expression in prostate cancer development, transfection of a plasmid containing rat C-CAM1 (the C-CAM isoform with a long cytoplasmic domain) cDNA into the human prostate tumor cell line PC-3, which does not express C-CAM, was found to greatly reduce the tumorigenicity of PC-3. 2 These results indicate that rat C-CAM1 has tumor-suppressive activity. Studies by Kunath et al 3 also showed that the expression of biliary glycoprotein 1 (bgp1) (the mouse homolog of C-CAM1) in mouse colon carcinoma cells was able to suppress the tumorigenicity of these cells in vivo. Taken together, these studies suggest that C-CAM1, with its tumor-suppressive activity, may be a promising agent for cancer therapy.
Although studies using rat C-CAM1 have shown great promise for cancer therapy, 4 there is concern that the human homolog of C-CAM1 (CD66a, also called BGP) is needed to avoid the possibility of immunological inactivation. Studies by Tripathy et al 5 with recombinant adenovirus (rAd) containing either the mouse or human erythropoietin gene in immunocompetent mice clearly showed that immunological responses toward homologous gene products from different species significantly diminish their therapeutic effects. Although human CD66a is homologous with rat C-CAM1 (with 65% similarity) and mouse bgp (69% similarity), there is no evidence to support human CD66a having tumor-suppressive activity. Using an Ad-transfer vector to achieve high efficiency CD66a transfection in the human prostate carcinoma cell line DU145, we demonstrated that restoring CD66a expression in DU145 cells ex vivo or in vivo markedly affected the malignant phenotype of these cells, as illustrated by their reduced ability to form tumors in a xenograft animal model.
MATERIALS AND METHODS

Ribonuclease (RNase) protection assay (RPA)
There are two variants of CD66a: one with a long (71 amino acids) cytoplasmic domain and one with a short (10 amino acids) cytoplasmic domain. The long cytoplasmic domain was obtained by polymerase chain reaction (PCR) of human colon cDNA prepared from RNA by reverse transcription. The PCR fragment was produced using oligo48 (5Ј-GAATTCCATT-TCGGGAAGACCGGCAGGGCA-3Ј; nucleotides 1357-1380) and oligo49 (5Ј-CTGCAGTGAGCAGGACAGGTTTCA-3Ј; nucleotides 1582-1605) as primers to produce a 255-base pair product. The EcoRI restriction site at the 5Ј of oligo48 (underlined) was added for cloning purposes. The PstI site in oligo49 (underlined) is part of the CD66a long-form sequence and is downstream of the termination codon. The 255-base pair PCR product was isolated and subcloned into pCRII to produce pCRII-CD66a-cyto, and the nucleotide sequence of the double-stranded DNA was determined. No nucleotide substitution was found.
The RNA probe made from pCRII-CD66a-cyto can distinguish CD66a from other CD66 family members that lack the cytoplasmic domain (i.e., CD66b, CD66c, and CD66e) or have cytoplasmic domains different from that of CD66a (i.e., CD66d). 6 In addition, this probe can simultaneously detect the expression of both short-and long-form CD66a. To synthesize antisense RNA probes, pCRII-CD66a-cyto was linearized with HindIII. Radiolabeled RNA probes were synthesized from the linearized DNA template using T7 RNA polymerase in the presence of [ 32 P]uridine triphosphate as described by Melton et al. 7 DNA templates were digested with RNase-free deoxyribonuclease I (Promega, Madison, Wis), and the labeled probes were used directly for RNase protection experiments.
Total cellular RNA was extracted from cells using RNAzol B (Tel-Test, Friendswood, Tex) and a purification protocol described by Chomczynski and Sacchi. 8 A total of 10 g of total RNA was hybridized with a 32 P-labeled antisense RNA probe and subjected to an RPA using the HybSpeed RPA kit (Ambion, Austin, Tex) according to the manufacturer's instructions.
Generation of human CD66a rAd
The full-length cDNA coding for long-form CD66a was obtained by PCR using the sequence information described by Hinoda et al. 9 Two isoforms generated from alternative splicing of RNA have been reported. 10 Using oligo primers for Nand C-terminal sequences and cDNA templates synthesized from human colon RNA, we only obtained DNA coding for the short-form variant of CD66a. Therefore, we decided to obtain the full-length, long-form CD66a by a three-step procedure. In the first step, we obtained the CD66a short-form sequence (including the extracellular domain, transmembrane domain, and short cytoplasmic domain) by PCR and subcloned the DNA into pCRII to produce pCR-CD66a-S. The cDNA encoding the long-form cytoplasmic domain of CD66a was also obtained by PCR and was subcloned into pCRII to give pCR-CD66a-cyto as described previously. The full-length cDNA coding for the full-length, long-form CD66a was then obtained by joining the long-form cytoplasmic domain and the short-form extracellular and transmembrane domains at the BsrFI site. The resultant long-form CD66a cDNA was cloned into pSK to generate pSK-CD66a-L.
The full-length, long-form CD66a DNA was then inserted into the Ad shuttle vector pXCMV 4 at the HindIII/NotI sites to generate pXCMV-CD66a-L. The entire CD66a long-form sequence in pXCMV-CD66a-L was confirmed by sequencing both sense and antisense strands of long-form CD66a using oligo primers that gave overlapping sequencing information ( Table 1) .
The rAd Ad-CD66a was generated by cotransfecting pX- CMV-CD66a-L and pJM17, which contain the Ad genome with the E1 gene deleted, into 293 cells by a previously published method. 11 Ad-CD66a was plaque-purified by reinfecting 293 cells. 12 Ad-CD66a was amplified by infecting 293 cells and was purified by double CsCl gradient centrifugation. The titer of the Ad-CD66a viral stock was determined to be 5 ϫ 10 10 plaque-forming units (PFU)/mL. To confirm that no DNA rearrangement or deletion had occurred during recombination, a series of PCRs was performed with rAd DNA prepared according to published procedures 11 using the primers shown in Table 1 . Primers XCMV1 and XCMV2, which flank the CD66a cDNA sequence, were used to detect the cDNA insert; primers XCMV3 and XCMV4 were used to detect the viral genome sequence. In addition, sense (oligo60 to oligo66) and antisense (oligo68 to oligo74) CD66a primers were used in combination with XCMV2 and XCMV1, respectively, to determine the orientation of the CD66a cDNA in the rAd. PCRs were performed according to published procedures.
11
Localization of CD66a protein by immunofluorescence staining DU145 cells were infected with rAd at multiplicities of infection (MOIs) of 10. After 72 hours, CD66a-expressing cells were fluorescently stained with an anticarcinoembryonic antigen (CEA) polyclonal antibody (Ab), which cross-reacts with CD66-family proteins, including CD66a, and fluorescein isothiocyanate-conjugated secondary Abs. The nuclei were stained with Hoechst 33342 and photographed on a Nikon (Melville, NY) microscope.
Western blotting
Cells were infected with Ad-CD66a or Ad-␤-galactosidase (␤-gal), a rAd containing the ␤-gal gene, at an MOI of 10 for 48 hours. These cells were then trypsinized, and total cell lysates were used for Western blot analysis. Protein concentration was determined by the method of Peterson. 13 Equal amounts of protein were separated by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, exposed to polyclonal rabbit anti-CEA Ab (Dako, Carpinteria, Calif), and detected by an enhanced chemiluminescence assay.
Aggregation assay
DU145 cells were infected with Ad-␤-gal or Ad-CD66a virus at an MOI of 10 for 48 hours. The cells were harvested by trypsin treatment and resuspended in minimal essential medium (MEM), and single-cell suspensions were made by repeated pipetting. The ability of these cells to aggregate was monitored while they were subjected to constant mixing at room temperature. At various time intervals, aliquots of control cells or virus-infected cells were removed. The numbers of single cells in these aliquots were counted with a hemocytometer.
Measurement of tumor growth in vivo after infection of DU145 cells with rAd in vitro
Ad-␤-gal-or Ad-CD66a-infected DU145 cells were cultured for 48 hours, harvested, and resuspended in MEM. Cells (2 ϫ 10 6 cells in a total volume of 100 L) were injected subcutaneously (s.c.) into the flanks of nu/nu mice. Tumor sizes were monitored weekly. The sizes of the tumors were calculated by the following formula: length ϫ width ϫ height ϫ 0.5236, according to Rockwell et al. 19 The levels of CD66a expression in three human prostatic cancer cell lines established from patients with prostatic carcinoma metastasized to lymph node (LNCaP 15 ), brain (DU145 16 ), and bone (PC-3 17 ) were tested by RPA using a probe generated from the cytoplasmic domain of CD66a. RNase protection analyses showed that none of the three prostate cancer cell lines contained detectable amounts of CD66a mRNA (Fig 1) . RNA from the colon carcinoma cell line HT-29, which was shown previously to express CD66a, 6, 18 showed strong protected bands of ϳ249 and 179 nucleotides (nt), which are the lengths of the expected fragments from the long and short cytoplasmic domains, respectively, of CD66a (Fig 1) . The prostate cancer cell lines examined did not express either isoform of CD66a. These observations are consistent with a previous immunohistochemical study of human prostate cancer tissues that showed a complete loss of CD66a expression in prostate carcinoma. 19 
RESULTS
Absence of
CD66a mRNAs in prostate cancer cell lines In the normal prostate, CD66a was expressed in the membrane of basal epithelial cells, suggesting that it may have functions related to cell-cell interaction among basal cells or between basal and luminal epithelial cells.
Recombinant virus identification
The significance of loss of CD66a in the prostate cancer cell lines was examined by reintroducing CD66a into DU145 cells using Ad-CD66a. Ad-CD66a DNA was analyzed by PCR to ensure that no deletion or rearrangement had occurred during viral generation by homologous recombination. PCR of the rAd DNA was performed as described in Materials and Methods using several primer sets to amplify the entire CD66a coding region as overlapping fragments (Fig 2A) . The nucleotide sequences of these primers are shown in Table 1 . The resulting PCR products are shown in Fig 2B. In addition, the primers (XCMV3 and XCMV4) were used to amplify the viral sequence between 11 and 13.4 map units (mu). The sizes of all PCR products matched the predicted sizes of the corresponding DNA fragments (Fig 2, A and B) , which indicated that Ad-CD66a contained the entire cDNA coding for the long-form CD66a protein.
Biochemical assessment of transgene expression
The surface expression of CD66a in DU145 cells was examined by immunofluorescence staining with polyclonal anti-CEA Ab. Cells expressing CD66a protein showed increased Ab staining, and the staining was most prominent on the cell surface and between cell-cell contact (Fig 3) . The expression of CD66a protein was further confirmed by Western immunoblot analysis. Although the predicted molecular mass of CD66a is 55 kDa, the purified CD66a protein has been reported to have a molecular mass of 100 -130 kDa because of extensive glycosylation. 20, 21 As shown in Figure 4 , a 130-kDa protein was detected in cells infected with Ad-CD66a virus, but not in the control DU145 cells or control Ad-␤-gal-infected cells (Fig 4) . As expected, several other proteins (possibly other CD66 family proteins) that cross-reacted with the anti-CEA Ab were also detected in all samples.
Cell adhesion activity
To determine whether the CD66a protein expressed from Ad-CD66a was functional, we assessed the ability of CD66a to confer cell adhesion activity. Parental DU145 cells and cells infected with Ad-CD66a or AdLuc, a rAd containing the luciferase gene, were analyzed by an in vitro aggregation assay as described in Materials and Methods. Cell aggregation occurred in the AdCD66a-infected cells but not in uninfected or Ad-Lucinfected cells (Fig 5) , indicating that the expressed CD66a protein was functional.
Effect on tumorigenicity
The effect of CD66a expression on the malignant potential of DU145 cells was examined in a nude mouse xenograft model. DU145 cells were infected in vitro with Ad-CD66a or Ad-␤-gal (as a control) and injected s.c. into male nu/nu mice. The tumors that developed from control Ad-␤-gal-infected cells grew continuously, whereas the tumors that developed from Ad-CD66a-infected cells grew slower initially, eventually stopped growing, and regressed at 4 weeks postinoculation (Fig  6) . At 54 days, the tumors from Ad-CD66a-infected cells averaged Ͻ20 mm 3 , whereas those from Ad-␤-gal-infected cells averaged 120 mm 3 . These results suggest that restoring the expression of CD66a protein in DU145 cells markedly suppressed the malignant phenotype of these cells. Thus, CD66a may play a significant role in determining the neoplastic phenotype of prostate cancer cells.
The effect of Ad-CD66a on the growth of established tumors was examined by the direct injection of AdCD66a into DU145 human prostate tumor xenografts in nude mice. Tumors were established in nude mice by the injection of DU145 cells into the flanks; Ad-CD66a was injected when the tumors reached 15 mm 3 . Tumor growth was inhibited with 3 ϫ 10 9 PFU of viruses divided in three equal injections at 2-week intervals ( Fig  7A) . The growth inhibition observed with Ad-CD66a was statistically different from that observed with the control Ad-Luc (P Ͻ .02). With a total of 6 ϫ 10 9 PFU of Ad-CD66a injected in three equal doses at the same (2-week) intervals, there was a more profound inhibition of tumor growth (Fig 7B) . This observation suggests that the antitumor effect of Ad-CD66a is dose-dependent. In fact, four of five tumors regressed completely after receiving 2 ϫ 10 9 PFU per injection at 2-week intervals (data not shown). These in vivo results indicate that increasing CD66a expression by gene therapy could be a promising approach for the treatment of patients with locally advanced prostate cancer.
DISCUSSION
In this study, we showed that the expression of human CD66a protein in DU145 human prostatic cancer cells reduced the ability of these cells to form tumors in a xenograft animal model. Thus, this study provides direct evidence that human CD66a does indeed have tumorsuppressive activity. These results indicate that AdCD66a has potential for prostate cancer therapy, and that further studies of Ad-CD66a in the treatment of locally advanced prostate cancer are warranted.
CD66a, like its rat homolog C-CAM, was shown to be a cell adhesion molecule when expressed in vitro 20 and was thus postulated to have functions in maintaining the communication of epithelial cells. During early fetal liver development, C-CAM transcript is not detectable, but a dramatic increase occurs immediately after birth, 22, 23 suggesting a correlation between C-CAM expression and hepatocyte differentiation. Indeed, C-CAM has been expressed in many differentiated tissues, including hepatocytes and the epithelia of capillaries, granulocytes, platelets, intestines, kidney, 24 and prostate. 1 A pathological study revealed that CD66a expression is lost in poorly, moderately, and well-differentiated prostate cancers. 19 Furthermore, a decrease in CD66a staining was observed in benign prostate hyperplasia and prostatic intraepithelial neoplasia. 19 These results indicate that a down-regulation of CD66a is associated with abnormal growth of the prostate. A decrease in CD66a expression was also observed in rat hepatic carcinomas, [25] [26] [27] [28] mouse colonic tumors, 29 and primary human colorectal tumors. 30 These observations, when taken together with the fact that CD66a expression correlates with hepatocyte differentiation, 22, 23 suggest that the decrease in CD66a expression may be associated with cell proliferation.
How C-CAM is down-regulated during carcinogenesis is not clear. The CD66a gene is located on the long arm Figure 2 . Ad-CD66a genome structure. A: The Ad5 genome is ϳ36 kilobases (kb) divided into 100 (1 mu ϭ 0.36 kb). 13 The CD66a gene was expressed from the human cytomegalovirus promoter. The entire expression cassette, including the cytomegalovirus promoter, CD66a cDNA, and the simian virus 40 early polyadenylation signal (a total of 2.6 kb) was used to replace the E1 region (1.3-9.2 mu). The relative locations of the PCR primers are shown. B: Gel analysis of PCR products. The primer sets used for PCR and the sizes of the expected PCR products are indicated.
of chromosome 19, which is not grossly altered in prostate cancer; therefore, it is unlikely that gene deletions are the reason for the loss of or reduction in human C-CAM expression. Studies by Rosenberg et al 29 consistently showed that neither chromosomal rearrangements nor gene deletions occurred close to the mouse C-CAM genes in mouse colon carcinomas or cell lines.
The possibility that a decreased expression of C-CAM in mouse colon carcinomas may result from a modification of the methylation of the promoter region has been examined. Hypomethylation of the C-CAM gene was detected in some carcinoma samples. 29 This finding is in contrast to the E-cadherin cell adhesion molecule, as DNA hypermethylation was shown to be the major mechanism of E-cadherin-silencing in human breast and prostate carcinomas. 31 Transcriptional regulation of the C-CAM gene has also been studied. The rat, mouse, and human C-CAM promoter sequences have been cloned and analyzed. [32] [33] [34] These genes do not contain TATA or CAAT boxes but do contain potential binding sites for basal and regulatory transcriptional elements. Using a gel-shift assay, Hauck et al 33 have shown that nuclear factors including upstream stimulatory factor, hepatic nuclear factor-4, and an activator protein-2-like molecule can bind to the human C-CAM promoter region. However, it is not clear whether these transcription factors are involved in the regulation of C-CAM gene expression during carcinogenesis.
Understanding the mechanism by which CD66a elicits its antitumor activity will be important for the develop- ment of CD66a as a cancer therapy. To date, we have seen no evidence of apoptosis as a result of CD66a overexpression (data not shown). In addition, CD66a-mediated growth inhibition did not require the presence of functional p53 or retinoblastoma (Rb) protein, because CD66a was able to elicit its tumor-suppressive effect in DU145 cells, which lack functional p53 35 and Rb proteins. 36 Therefore, CD66a functions by a p53-and Rb-independent pathway. However, the mechanism by which CD66a elicits its tumor-suppressive activity remains unknown. This mechanism probably involves a novel signal-transduction pathway that leads to growth inhibition.
The effect of Ad-CD66a on the growth of established tumors suggests that CD66a could be used in the treatment of prostate cancers. Ad-CD66a may also be useful in the treatment of a wide spectrum of human cancers in which CD66a has a role in carcinogenesis. We have shown that the prostate cancer cell line DU145 is easily infected by Ad, and that the expression of recombinant human CD66a protein suppressed the tumorigenicity of DU145 cells. These observations suggest that Ad-CD66a might be useful in the treatment of prostate cancer. However, there are practical issues related to the use of an Ad as a vector for gene therapy. These are: (a) whether a therapeutic effect can be achieved without stable and long-term expression of CD66a, (b) whether an immune response will reduce the efficiency of transgene expression if multiple infection is required, and (c) whether tumor growth can be effectively suppressed without infection of all tumor cells in light of the limited ability of Ads to penetrate solid tumors. In this regard, several interesting observations from a recent phase I trial of Ad-mediated p53 gene therapy in patients with advanced recurrent head and neck squamous cell carcinoma may provide some answers.
Using Ad vector in immunocompetent patients, Clayman et al 37 observed that although patients developed anti-Ad5 Abs over the course of treatment, this response did not block transduction and expression of the p53 transgene. Neither was the immune response to Ad deleterious to the patients. In this p53 phase I study, the sizes of the tumors were relatively large. Based on previous results on the spread of Ad after intratumoral injection, 38 one might expect only a minority of tumor 
